Antiviral agents are critical tools in the management and treatment of viral infections. These compounds act by targeting various stages of the viral life cycle, including viral entry, replication, assembly, and release. With the rising burden of viral diseases such as HIV, hepatitis, influenza, and emerging pathogens like SARS-CoV-2, the development and availability of effective antiviral drugs have become paramount. 

Mechanisms of Action of Antiviral Agents

Antiviral drugs can be broadly classified based on the stage of the viral life cycle they target:

• Inhibitors of viral entry and fusion: These agents prevent the virus from attaching to or penetrating host cells. Examples include fusion inhibitors and agents that alter endosomal pH to block viral fusion (e.g., chloroquine, hydroxychloroquine).
• Uncoating inhibitors: Drugs such as amantadine interfere with the release of viral genetic material inside the host cell.
• Polymerase inhibitors: Nucleoside and nucleotide analogues (e.g., remdesivir, favipiravir, acyclovir) inhibit viral RNA or DNA polymerases, causing premature termination of viral genome replication.
• Protease inhibitors: Compounds like ritonavir and lopinavir block viral proteases required for processing viral polyproteins into functional units, thereby preventing viral maturation.
• Integrase inhibitors: These block the integration of viral DNA into the host genome, a critical step in retroviral replication (e.g., raltegravir).
• Immunomodulators: Agents such as nitazoxanide enhance host antiviral responses by amplifying interferon pathways and cytoplasmic RNA sensing.

The combination of antiviral agents with different mechanisms is often employed to enhance efficacy and prevent the emergence of drug-resistant viral strains.

Clinical Applications

• HIV/AIDS: Combination antiretroviral therapy targets reverse transcriptase, protease, and integrase enzymes.
• Hepatitis B and C: Polymerase and protease inhibitors are central to current treatment regimens.
• Herpesviruses: DNA polymerase inhibitors like acyclovir are standard treatments.
• Influenza: Neuraminidase inhibitors prevent viral release from infected cells.
• Emerging viruses: Drugs such as remdesivir and favipiravir have been repurposed or developed for SARS-CoV-2 treatment.

Antiviral agents are indispensable in combating viral diseases by targeting multiple stages of the viral life cycle. Advances in understanding viral replication and host interactions have facilitated the development of diverse antiviral compounds with improved efficacy and safety profiles. Our extensive portfolio of antiviral agents empowers researchers and clinicians to advance antiviral strategies and improve patient outcomes.